Emerging Market and Trends in Global Autoimmune Monoclonal Antibodies April.2017 | Page 2

Global Autoimmune Monoclonal Antibodies Market According to the report “Autoimmune Monoclonal Antibodies Market”, published by Market Data Forecast, the global market is projected to reach USD 25,274.7 million by 2021, at a CAGR of 7.84% from 2016 to 2021. Irregular functioning of humans’ immune system results in autoimmune disorders. Overproduction of self-reactive immune cells (such as antibodies & T-cells) damage regular functions of /cells/tissues/organs. This lead to different autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and others diseases. Typically, drugs are used as a treatment to cure autoimmune disorders. The adverse effects associated with drugs has made switched to concentrate on monoclonal antibodies. Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat wide array of diseases that are related to immune response. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells. Global Autoimmune Monoclonal Antibodies market is expected to witness growth owing to growing research & development to stimulate the development of monoclonal antibodies rising number of patients with autoimmune diseases, and increasing public & private organizations involvement to support advanced therapeutics development. In addition, rising demand for antibody based therapeutics, increasing adoption of advanced healthcare therapeutics, and growing number of lifestyle associated disorders are further promoting the growth of global autoimmune monoclonal antibodies. Global Market for Autoimmune Monoclonal Antibodies is segmented on the basis of source, application, end user and region. 1. On the basis of Source     Murine Chimeric Humanized Human 2. On the basis of Application      Systemic Lupus Erythematosus Rheumatoid Arthritis Multiple Sclerosis Transplant Rejection/Graft Versus Host Disease Others 3. On the basis of End User  Hospitals/Clinics [phone] | www.marketdataforecast.com | [email protected]